| |
OR
|
95% CI
|
P-value
|
|---|
|
DAS28-ESR, no remission
|
|
Disease duration, years
|
1.02
|
1.00–1.05
|
0.10
|
|
Positive for rheumatoid factor
|
2.18
|
1.47–3.22
|
< 0.00
|
|
Previous use of bDMARDs
|
4.37
|
2.00–9.54
|
< 0.00
|
|
Presence of FAA
|
3.43
|
2.01–5.84
|
< 0.00
|
|
DAS28-CRP, no remission
|
|
Presence of lung disease
|
3.53
|
1.08–11.53
|
0.04
|
|
Positive for rheumatoid factor
|
1.64
|
1.18–2.29
|
< 0.00
|
|
Previous use of bDMARDs
|
4.25
|
2.47–7.31
|
< 0.00
|
|
Presence of FAA
|
3.59
|
2.43–5.33
|
< 0.00
|
|
SDAI, no remission
|
|
Previous use of bDMARDs
|
6.77
|
2.13–21.5
|
< 0.00
|
|
Presence of FAA
|
6.33
|
2.75–14.6
|
< 0.00
|
|
CDAI, no remission
|
|
Previous use of bDMARDs
|
5.94
|
1.44–24.49
|
< 0.00
|
|
Presence of FAA
|
7.59
|
2.37–24.33
|
< 0.00
|
|
RAPID, no remission
|
|
Use of MTX
|
2.6
|
0.94–7.23
|
0.07
|
|
Previous use of bDMARDs
|
8.22
|
2.59–26.11
|
< 0.00
|
|
Presence of FAA
|
5.57
|
2.69–11.52
|
< 0.00
|
- aFactors known to be associated with remission such as age, disease duration, the positivity of RF, positivity of anti-cyclic citrullinated peptide, the existence of lung disease, use of MTX, previous use of bDMARDs were included for multivariate logistic regression analysis
